Episode 159: Thomas Bollyky on patent waivers, plus vaccine riches, & a gene therapy for aging
First, Moderna and Pfizer are poised to make billions of dollars from their Covid-19 vaccines this year, and we discuss what that massive infusion of cash portends for both companies. Next, Thomas Bollyky of the Council on Foreign Relations joins us to explain what the U.S.'s support for waiving Covid-19 vaccine patents means \u2014 and doesn\u2019t mean \u2014 for the global vaccination effort. Finally, STAT\u2019s Megan Molteni calls in to share the story of a little-known biotech company recruiting patients to Mexico with the promise of an anti-aging gene therapy in an unregulated clinical trial.